iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/15655773
Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Feb 15;191(4):507-14.
doi: 10.1086/427242. Epub 2005 Jan 14.

Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice

Thomas C Greenough  1 , Gregory J Babcock, Anjeanette Roberts, Hector J Hernandez, William D Thomas Jr, Jennifer A Coccia, Robert F Graziano, Mohan Srinivasan, Israel Lowy, Robert W Finberg, Kanta Subbarao, Leatrice Vogel, Mohan Somasundaran, Katherine Luzuriaga, John L Sullivan, Donna M Ambrosino
Affiliations

Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice

Thomas C Greenough et al. J Infect Dis. .

Abstract

Background: Severe acute respiratory syndrome (SARS) remains a significant public health concern after the epidemic in 2003. Human monoclonal antibodies (MAbs) that neutralize SARS-associated coronavirus (SARS-CoV) could provide protection for exposed individuals.

Methods: Transgenic mice with human immunoglobulin genes were immunized with the recombinant major surface (S) glycoprotein ectodomain of SARS-CoV. Epitopes of 2 neutralizing MAbs derived from these mice were mapped and evaluated in a murine model of SARS-CoV infection.

Results: Both MAbs bound to S glycoprotein expressed on transfected cells but differed in their ability to block binding of S glycoprotein to Vero E6 cells. Immunoprecipitation analysis revealed 2 antibody-binding epitopes: one MAb (201) bound within the receptor-binding domain at aa 490-510, and the other MAb (68) bound externally to the domain at aa 130-150. Mice that received 40 mg/kg of either MAb prior to challenge with SARS-CoV were completely protected from virus replication in the lungs, and doses as low as 1.6 mg/kg offered significant protection.

Conclusions: Two neutralizing epitopes were defined for MAbs to SARS-CoV S glycoprotein. Antibodies to both epitopes protected mice against SARS-CoV challenge. Clinical trials are planned to test MAb 201, a fully human MAb specific for the epitope within the receptor-binding region.

PubMed Disclaimer

Figures

Figure 3.
Figure 3.
Epitope mapping by immunoprecipitation. Truncated fragments of surface (S) glycoprotein of severe acute respiratory syndrome (SARS)—associated coronavirus (right) were tagged with 6-histidine (His) epitopes and were immunoprecipitated with monoclonal antibody (MAb) 68 (top left), MAb 201 (middle left), or nickel-nitrilotriacetic acid (Ni-NTA) agarose (bottom left); resolved by SDS-PAGE; transferred to solid support; and then visualized using anti-His (C-term) antibody, followed by a 1:5000 dilution of horseradish peroxidase-conjugated goat anti-mouse IgG, treatment with enhanced chemiluminescence reagent, and autoradiography. In the right panel, epitopes are depicted for MAb 201 (490–510 [blackened boxes]) and MAb 68 (130–150 [shaded boxes]).
Figure 1.
Figure 1.
In vitro characterization of monoclonal antibodies (MAbs) 201 and 68. A, Results of flow-cytometry analysis of human epithelial kidney—293T/17 cells expressing full-length surface (S) glycoprotein (S1255) of severe acute respiratory syndrome (SARS)-associated coronavirus. Cells were stained with either MAb 201 (circles) or MAb 68 (squares), followed by phycoerythrin-labeled goat anti-human IgG. B, Results for Vero E6 cells incubated with 10 nmol/L of a c-Myc (human proto-oncogene) epitope-tagged protein consisting of the first 590 aa of S glycoprotein (S590), in the presence of various concentrations of MAb 201 (circles) or MAb 68 (squares). S glycoprotein binding was detected via the epitope tag using the murine anti-c-Myc antibody 9E10, followed by phycoerythrin-labeled goat anti-mouse IgG. Reduction in fluorescent intensity mediated by the MAb was calculated and plotted.
Figure 2.
Figure 2.
Patterns of inhibition of cytopathic effects (CPEs) in microneutralization assays. A, Results of infection of Vero E6 cells with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV), preincubated with either monoclonal antibody (MAb) 201 (circles) or MAb 68 (squares) at various concentrations. After 3 days of incubation, CellTiter96 reagent was added to measure the metabolic activity of cells. Protective effect was calculated as described in Materials and Methods and plotted. B, Dilution series for each MAb incubated with SARS-CoV and subsequently added to Vero E6 cells in triplicate. Three days postinfection, individual wells were graded by the percentage of cells involved in the CPE, as shown in the key (right). C, Photographs demonstrating results of microscopic examination of infected Vero E6 cells. This experiment was identical to that described for panel B, with the exception that the virus inoculum was 3000 TCID50/well, instead of the standard 100 TCID50/well. Arrows indicate small foci of CPE observed in the presence of MAb 68 at 150 nmol/L but not of MAb 201 at 150 nmol/L. More-extensive CPE was seen in the presence of both MAbs at the lowest concentration of 9.4 nmol/L.
Figure 4.
Figure 4.
Efficacy of immunoprophylaxis in mice challenged with severe acute respiratory syndrome (SARS)—associated coronavirus (SARS-CoV). Mice (4 in each group) were treated with the indicated monoclonal antibody (MAb), at estimated doses of 40, 8, and 1.6 mg/kg, 1 day prior to intranasal challenge with 105 TCID50 of SARS-CoV. Two days after infection, lung tissue (A) or nasal turbinate tissue (B) was harvested and homogenized, and in vitro virus-titration assays were performed. Virus titers are shown as mean log10 TCID50 per gram of tissue, with standard errors. Comparisons of the results between groups were made by use of the nonparametric, 2-tailed Mann-Whitney test. *P > .05, compared with control. The limit of detection of the assay is indicated (A, dashed line).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–76. - PubMed
    1. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953–66. - PubMed
    1. World Health Organization (WHO) China confirms SARS infection in another previously reported case; summary of cases to date—update 5 2004. Geneva: WHO; [Accessed 3 January 2005]. http://www.who.int/csr/don/2004_04_30/en.
    1. Bisht H, Roberts A, Vogel L, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA. 2004;101:6641–6. - PMC - PubMed
    1. Bukreyev A, Lamirande EW, Buchholz UJ, et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet. 2004;363:2122–7. - PMC - PubMed

Publication types

MeSH terms